Effects of sodium–glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes in people with diabetes and advanced chronic kidney disease
Main finding · MACE compositeResult — go to the resultHazard ratio 0.65 95% CI 0.43–0.99Authors' conclusion
In patients with CKD who were treated with an SGLT2i, continuation of SGLT2i use after eGFR declined to 30 ml/min per 1.73 m2 or less was associated with lower risks of cardiovascular and renal events compared with discontinuation of SGLT2i use. Continued use of SGLT2i throughout the course of CKD should be considered to optimise patient outcomes.
Study context
- Population
- Patients with T2D prescribed an SGLT2i (2016–2021) who subsequently had eGFR <30 ml/min per 1.73 m² on two occasions at least 90 days apart
- Participants
- 337 vs 358
- Exposure
- SGLT2i continuation vs discontinuation after eGFR <30 ml/min per 1.73 m²
- Continuationn = 337
- Discontinuationn = 358reference
- Outcome
- MACE composite
Methodological detailstwo institutions, inverse probability of treatment weighting (IPTW)
- Two institutions
- Inverse probability of treatment weighting (IPTW)
Main finding
As reported in the abstract
Hazard ratio
0.65
95% CI 0.43–0.99
Continuationvs Discontinuation
HR 0.65 (95% CI 0.43–0.99)
Observational data: associations, not effects.
Further findings
| Outcome | SHR (95% CI) | |
|---|---|---|
| MI · during follow-up | 0.43 (0.21–0.89) | |
| eGFR decline of ≥50% | 0.58 (0.42–0.81) | |
| All-cause hospital admission | 0.77 (0.64–0.94) | |
| 0.20.5125Subdistribution hazard ratio (log scale) |
Blood haemoglobin · end of follow-up
difference 4.12 · P = 0.047
Safety
- None of the studied safety outcomes were significantly different between groups
Original publication
Effects of sodium–glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes in people with diabetes and advanced chronic kidney disease. Diabetologia. Published 29 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →